Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Athira Pharma, Inc.    ATHA


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

SK Biopharmaceuticals and LifeSci Venture Partners Forge Ties for Open Innovation

11/02/2020 | 06:54am EST

Pangyo - SK Biopharmaceuticals,Co.,Ltd., a global innovative pharmaceutical company, announced today the company has signed an agreement with the global life science venture capital firm LifeSci Venture Partners to collaborate on open innovation through a fund.

The fund will invest primarily in private healthcare companies developing novel therapies and innovative technologies.

'As a strategic investor in the fund, SK Biopharmaceuticals plans to enhance its global competitiveness by expanding its partnerships with promising ventures for further growth,' said Changho Yu, Chief Strategy Officer of SK Biopharmaceuticals. 'This partnership for open innovation is an important step forward that builds on our nearly three decades of research and development expertise.'

Paul Yook, Partner & Chief Investment Officer of LifeSci Venture Partners, added, 'We are pleased to start this new collaboration with SK Biopharmaceuticals, a company that shares our passion and commitment to bringing innovative solutions to the healthcare system. By combining our expertise and connections in the life sciences industry and beyond, we aim to help promising early ventures accelerate scientific breakthroughs and technological innovations.'

SK Biopharmaceuticals discovered and developed two innovative and approved medicines cenobamate and solriamfetol. Cenobamate was approved by the U.S. Food and Drug Administration (FDA), launching in May of 2020, and is being commercialized in the U.S. by the company's subsidiary SK life science. The company also discovered and licensed-out solriamfetol, a treatment approved by the FDA and the European Medicines Agency. SK Biopharmaceuticals maintains the rights to develop and commercialize solriamfetol in 12 countries in Asia.

About SK Biopharmaceuticals Co., Ltd.

SK Biopharmaceuticals and its U.S. subsidiary SK life science are global pharmaceutical companies focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS). The companies have a pipeline of eight compounds in development for the treatment of CNS disorders, including epilepsy. Additionally, SK Biopharmaceuticals is focused on early research in oncology.

Both SK Biopharmaceuticals and SK life science are part of SK Group, one of the largest conglomerates in Korea. SK Holdings, the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Holdings is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses.

About LifeSci Venture Partners

Formed in 2017, LifeSci Venture Partners is the early stage investing arm of LifeSci Partners, a unique life sciences and healthcare consultancy formed in 2010. It focuses on pre-public institutional rounds of transformational healthcare companies managed by exceptional founder/entrepreneurs. Its most recent fund, LifeSci Venture Partners II, LP (the 'Fund') was launched in 2020 and has made private investments in numerous companies with novel oncology and CNS expertise including Erasca, Athira Pharma (NASDAQ: ATHA), Allievex Corporation, Science 37 and Senti Bio. ELA Partners, LLC acted as exclusive placement agent for the Fund's capital raise.

About Cenobamate

Cenobamate was discovered and developed by SK Biopharmaceuticals and SK life science. While the precise mechanism by which cenobamate exerts its therapeutic effect is unknown, it is believed to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. It is also a positive allosteric modulator of the -aminobutyric acid (GABAA) ion channel.

Cenobamate is approved in the United States as an anti-seizure medication (ASM) for the treatment of partial-onset seizures in adults, and is available under the brand name XCOPRI (cenobamate tablets) CV. SK Biopharmaceuticals has an exclusive licensing agreement with Arvelle Therapeutics GmbH to develop and commercialize cenobamate in Europe and an exclusive licensing agreement with Ono Pharmaceutical to develop and commercialize cenobamate in Japan.


Email: h.p.comm@sk.com

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
ATHIRA PHARMA, INC. -1.44% 26.405 Delayed Quote.-21.78%
SK BIOPHARMACEUTICALS CO., LTD. -1.29% 153000 End-of-day quote.-9.47%
SK HOLDINGS CO., LTD -1.14% 302500 End-of-day quote.25.78%
All news about ATHIRA PHARMA, INC.
01/11ATHIRA PHARMA, INC. : Change in Directors or Principal Officers, Regulation FD D..
01/07Athira Pharma to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020ATHIRA PHARMA, INC. : Change in Directors or Principal Officers, Financial State..
2020Athira Pharma Announces Appointment of Kelly A. Romano to its Board of Direct..
2020ATHIRA PHARMA : Awarded $15 Million Grant from National Institute on Aging to Su..
2020Athira Pharma Secures $15 Million Grant to Advance Clinical Trial of Alzheime..
2020Athira Pharma Awarded $15 Million Grant from National Institute on Aging to S..
2020ATHIRA PHARMA : Announces Initiation of Patient Dosing for ACT-AD Clinical Trial..
2020Athira Pharma Begins Dosing Patients in Phase 2 Study of Drug to Treat Alzhei..
2020ATHIRA PHARMA : Announces Initiation of Patient Dosing for ACT-AD Clinical Trial..
More news
Financials (USD)
Sales 2020 0,06 M - -
Net income 2020 -24,8 M - -
Net cash 2020 209 M - -
P/E ratio 2020 -14,7x
Yield 2020 -
Capitalization 870 M 870 M -
EV / Sales 2020 11 603x
EV / Sales 2021 -
Nbr of Employees 15
Free-Float 94,5%
Duration : Period :
Athira Pharma, Inc. Technical Analysis Chart | ATHA | US04746L1044 | MarketScreener
Technical analysis trends ATHIRA PHARMA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 4
Average target price 44,25 $
Last Close Price 26,79 $
Spread / Highest target 90,4%
Spread / Average Target 65,2%
Spread / Lowest Target 34,4%
EPS Revisions
Managers and Directors
Leen Kawas President, Chief Executive Officer & Director
John M. Fluke Chairman
Mark J. Litton Chief Operating Officer
Glenna Mileson Chief Financial Officer & Secretary
Hans Moebius Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.24.17%51 332
LONZA GROUP AG3.31%49 176
CELLTRION, INC.-8.36%43 849
SEAGEN INC.0.41%31 812